{
    "article_id": "bfed9b3b-1e03-41a2-b9ce-17cdc28c3262",
    "extracted_text": "cancers\nArticle\nCost-Effectiveness of Artificial Intelligence Support in\nComputed Tomography-Based Lung Cancer Screening\nSebastianZiegelmayer*,\u2020,MarkusGraf\u2020,MarcusMakowski,JoshuaGawlitza\u2020 andFelixGassert\u2020\nInstituteofDiagnosticandInterventionalRadiology,SchoolofMedicine,KlinikumRechtsderIsar,\nTechnicalUniversityMunich,IsmaningerStra\u00dfe22,81675Munich,Germany;markus.m.graf@tum.de(M.G.);\nmarcus.makowski@tum.de(M.M.);joshua.gawlitza@tum.de(J.G.);felix.gassert@tum.de(F.G.)\n* Correspondence:s.ziegelmayer@tum.de\n\u2020 Theseauthorscontributedequallytothiswork.\nSimpleSummary:Lungcancerscreeningwithlow-doseCT(LDCT)hasbeenshowntosignificantly\nreducecancer-relatedmortalityandisrecommendedbytheUnitedStatesPreventiveServicesTask\nForce(USPSTF).WithpendingrecommendationinEuropeandmillionsofpatientsenrollinginthe\nprogram,deeplearningalgorithmscouldreducethenumberoffalsepositiveandnegativefindings.\nTherefore, we evaluated the cost-effectiveness of using an AI algorithm for the initial screening\nscanusingaMarkovsimulation. WefoundthatAIsupportatinitialscreeningisacost-effective\nstrategyuptoacostofUSD1240perpatientscreening,givenawillingness-to-payofUSD100,000\nperquality-adjustedlifeyears(QALYs).\n(cid:1)(cid:2)(cid:3)(cid:1)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:1) Abstract:Background:LungcancerscreeningisalreadyimplementedintheUSAandstronglyrec-\n(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)\nommendedbyEuropeanRadiologicalandThoracicsocietiesaswell.Uponimplementation,thetotal\nCitation:Ziegelmayer,S.;Graf,M.; numberofthoraciccomputedtomographies(CT)islikelytorisesignificantly.Asshowninprevious\nMakowski,M.;Gawlitza,J.;Gassert, studies,modernartificialintelligence-basedalgorithmsareon-parorevenexceedradiologist\u2019sperfor-\nF.Cost-EffectivenessofArtificial manceinlungnoduledetectionandclassification.Therefore,theaimofthisstudywastoevaluatethe\nIntelligenceSupportinComputed cost-effectivenessofanAI-basedsysteminthecontextofbaselinelungcancerscreening.Methods:In\nTomography-BasedLungCancer\nthisretrospectivestudy,adecisionmodelbasedonMarkovsimulationwasdevelopedtoestimate\nScreening.Cancers2022,14,1729.\nthequality-adjustedlife-years(QALYs)andlifetimecostsofthediagnosticmodalities. Literature\nhttps://doi.org/10.3390/\nresearchwasperformedtodeterminemodelinputparameters.Modeluncertaintyandpossiblecosts\ncancers14071729\noftheAI-systemwereassessedusingdeterministicandprobabilisticsensitivityanalysis.Results:In\nAcademicEditors:HamidKhayyam, thebasecasescenarioCT+AIresultedinanegativeincrementalcost-effectivenessratio(ICER)as\nAliMadani,RaheleKafiehand comparedtoCTonly,showinglowercostsandhighereffectiveness.Thresholdanalysisshowedthat\nAliHekmatnia\ntheICERremainednegativeuptoathresholdofUSD68fortheAIsupport.Thewillingness-to-payof\nReceived:1March2022 USD100,000wascrossedatavalueofUSD1240.Deterministicandprobabilisticsensitivityanalysis\nAccepted:23March2022 showedmodelrobustnessforvaryinginputparameters.Conclusion:Basedonourresults,theuseof\nPublished:29March2022 anAI-basedsystemintheinitiallow-doseCTscanoflungcancerscreeningisafeasiblediagnostic\nstrategyfromacost-effectivenessperspective.\nPublisher\u2019sNote:MDPIstaysneutral\nwithregardtojurisdictionalclaimsin\nKeywords:lungcancerscreening;deeplearning;cost-effectivenessanalysis;AI-supportsystem\npublishedmapsandinstitutionalaffil-\niations.\n1. Introduction\nCopyright: \u00a9 2022 by the authors. Basedonthefindingsofthenationallungscreeningtrial(NLST),in2014theUnited\nLicensee MDPI, Basel, Switzerland. States Preventive Service task force recommended the annual lung cancer screening of\nThis article is an open access article\npatientsbetween55and80yearswith20packyearsofsmokinghistory[1,2]. Incontrast\ndistributed under the terms and\nto the high and further increasing incidence of lung cancer globally, the incidence of\nconditionsoftheCreativeCommons\nlungcancerwasrelativelylowintheNLST.Nonetheless,theNLSTwasabletoshowa\nAttribution(CCBY)license(https://\nsignificantreductioninlungcancerrelatedmortalityduetotheannualscreeningwithlow-\ncreativecommons.org/licenses/by/\ndosecomputedtomography(CT).Consequently,aEuropeanPositionStatementfollowed\n4.0/).\nCancers2022,14,1729.https://doi.org/10.3390/cancers14071729 https://www.mdpi.com/journal/cancersCancers 2022, 13, x FOR PEER REVIEW 2 of 11\nCancers2022,14,1729 2of11\nin 2017, strongly recommending the CT-based lung cancer screening as well [3]. This rec-\noimnm20e1n7d,asttiroonn igsl yfurrethcoerm smupenpdorintegd tbhye tCheT -Dbaustechd-Bluenlggiacna nlucnerg-sccarneceenri nsgcreaesnwinegl ltr[i3a]l. (NThei-s\ndreercloamndms-eLneduavteionns Lisofnugrkthaenrkesur pSpcroeretnedingbsy OthnedDeruztocehk- B(NelEgiLaSnOlNun))g, -wcahniccehr aslcsroe eshnoinwgetdr iaa l\ns(iNgneidfiecralannt drse-dLuecutvioenn sinL olnugnkga cnaknecreSrc mreoenrtianlgitsyO fnodr ehrizgohe-kri(sNk EpLaStiOenNt)s) ,wwhhoic phaarltsiocisphaotewde dina\nthsieg nscifireceannitnrge d[4u]c. tWionithin seluvnegracl aonncgeorimngo rptialloitty pfroorjehcitgsh i-nr iEskurpoapteie, nthtse wwhidoepsaprrteicaidp aintetdroidnutch-e\ntisocnre oenf ilnugng[4 c]a.nWceitrh sscereveenrainlgo nsegeominsg tpo ibloet opnrloyje ac tmsianttEeru orof ptiem,teh. ewidespreadintroduction\nofluNngevcearnthceerlesscsr,e tehnei nbgenseefeimts sotfo lubnego ncalyncaemr sactrteeernoifntgim aree. limited by false negative and\nNevertheless,thebenefitsoflungcancerscreeningarelimitedbyfalsenegativeand\nfalse positive findings, which not only result in high costs but also affect clinical outcome\nfalsepositivefindings,whichnotonlyresultinhighcostsbutalsoaffectclinicaloutcome\nand quality of life [2,5,6]. Currently, low dose CT-scans in the screening setting are evalu-\nandqualityoflife[2,5,6].Currently,lowdoseCT-scansinthescreeningsettingareevaluated\nated based on standardized systems like Lung-RADS (Lung imaging reporting and data\nbasedonstandardizedsystemslikeLung-RADS(Lungimagingreportinganddatasystem),\nsystem), which improve the diagnostic accuracy for radiologists and reduces costs by de-\nwhichimprovethediagnosticaccuracyforradiologistsandreducescostsbydecreasingthe\ncreasing the need for further diagnostic tests [7,8]. Even after a recent revision of the re-\nneedforfurtherdiagnostictests[7,8]. Evenafterarecentrevisionofthereportingsystem,\nporting system, observer variability will remain a relevant limitation [9,10].\nobservervariabilitywillremainarelevantlimitation[9,10].\nThe rapid development of artificial intelligence (AI) in the medical field has shown\nTherapiddevelopmentofartificialintelligence(AI)inthemedicalfieldhasshown\npromising results for cancer screening and recent AI-models may achieve or exceed the\npromisingresultsforcancerscreeningandrecentAI-modelsmayachieveorexceedthe\ndiagnostic performance of sub-specialized experts, for example in breast cancer screening\ndiagnosticperformanceofsub-specializedexperts, forexampleinbreastcancerscreen-\n[11]. While long-standing CAD (computer aided diagnosis/detection) systems show\ning[11]. Whilelong-standingCAD(computeraideddiagnosis/detection)systemsshow\nmixed results for lung cancer detection [12\u201314], novel neural networks, convolutional neu-\nmixed results for lung cancer detection [12\u201314], novel neural networks, convolutional\nral networks (CNN) in particular, seem to have a positive effect on the diagnostic perfor-\nneuralnetworks(CNN)inparticular,seemtohaveapositiveeffectonthediagnosticperfor-\nmance of radiologists [15]. Ardila et al. showed that a 3D-CNN outperformed radiologists\nmanceofradiologists[15]. Ardilaetal. showedthata3D-CNNoutperformedradiologists\nin low-dose CT screening scans when no prior scans were available, indicating a favorable\ninlow-doseCTscreeningscanswhennopriorscanswereavailable,indicatingafavorable\nbenefit for screening initiation.\nbenefitforscreeninginitiation.\nAmong other constraints, the health economic impact of AI systems is an important\nAmongotherconstraints,thehealtheconomicimpactofAIsystemsisanimportant\nfactor in the decision to implement models in routine clinical practice. Despite the immi-\nfactorinthedecisiontoimplementmodelsinroutineclinicalpractice.Despitetheimminent\nnent deployment of lung cancer screening and the promising results of AI-systems, no\ndeploymentoflungcancerscreeningandthepromisingresultsofAI-systems,nostudy\nstudy has been performed to evaluate the utilization of neural networks in lung cancer\nhasbeenperformedtoevaluatetheutilizationofneuralnetworksinlungcancerscreening\nscreening compared to the stand-alone low dose CT-scan from an economic point of view.\ncomparedtothestand-alonelowdoseCT-scanfromaneconomicpointofview. Therefore,\nTherefore, the aim of our study was to evaluate the cost effectiveness of an AI-system for\ntheaimofourstudywastoevaluatethecosteffectivenessofanAI-systemfortheinitial\nthe initial scan of annual lung cancer screening and present the first results on identifying\nscan of annual lung cancer screening and present the first results on identifying a cost\na cost margin for a clinical integration.\nmarginforaclinicalintegration.\n22. .MMaateterriaialsls aanndd MMeeththooddss\n22.1.1. .MMooddeel lSStrtruucctuturree\nAA ddeceicsiisoionn mmodoedle ilncinlucdluindgin tghet hdeiadginaogsntiocs stticrastetrgaiteesg oief scoonfvceonntivoennatli oCnTa lanCdT CaTn aduCg-T\nmauengtmeden btye dAbI ywAasI wcraesatcerde aatnedd aunseddu asse da adsecaisdieocni stiroene,t arese s,haoswshno iwn nFiignuFrieg 1u.r e1.\nFFigiguurree 11. .M Ma ar rk ko ov m mo od de el lw wit ih p po oss si sb ible st sa tate tes so of fd dis ie sea ase a an nd tr ta ran nsi st ii to ion p pro rob ba ab bil ii lt ii te is sb bet ew twee en st sa tt ae ts e.\nv th le se d n e en s .\nBC = bronchial cancer; LT = life tables.\nBC=bronchialcancer;LT=lifetables.Cancers2022,14,1729 3of11\nForcalculationofcostsandbenefitsinthedifferentiterationsaMarkovtransitionstate\nmodelwascreated. Themodelincludedthestages:\n\u2022 NoBC(patientswithoutBC=truenegative);\n\u2022 NoBC,Suspiciousnodule(patientswithoutBCbutsuspiciousnodule=falsepositive);\n\u2022 BCundetected(patientswithundetectedBC=falsenegative);\n\u2022 BCafterresection(patientswithBCafterresection);\n\u2022 BCpalliative(patientswithBCwhichisunresectable/palliative);\n\u2022 Dead.\nAdditionally,forbettersimulationandunderstandingofthemodel,thestates\u201cBC\ndelayeddetection\u201dand\u201cBCearlydetection\u201dwerecreated,whichonlyservedfortransi-\ntion. TheMarkovmodelreflectsthedifferentstatesapatientcanbeassignedto. Taking\nintoaccounttransitionprobabilitiesbetweenthestatesaswellascostsandeffectiveness\n(displayedinQualityofLife)inthosestatesduringseveraliterations,cumulativecostsand\ncumulativeeffectivenesswithinadefinedtimehorizoncanbecalculatedbyaddingthose\nupthroughouttheiterations.\nAnalysisofthemodelwasperformedusingadedicateddecisionanalysissoftware\n(TreeAgeProVersion19.1.1,Williamstown,MA,USA).\n2.2. InputParameters\nTherewasnorequirementforanethicalapprovalforthisanalysisbasedoncommonly\navailable data. Model input parameters were based on current literature. Age-specific\nrisk of death was derived from the US life tables [16]. Age at the diagnostic procedure\nwassetto60yearsandwillingness-to-paywassettoUSD100,000perqualityadjusted\nlife year (QALY) at a discount rate of 3%, as reported previously [17,18]. The discount\nratereflectsthelossineconomicvalueoreffectivenesswhenthereisadelayinrealizing\nabenefitorincurringcosts. Thepre-testprobabilityofBCwassetto2.635%fortherisk\ngroupconsistingoffemaleandmalesmokersriskforanintervalof30years,accordingto\npublisheddatafromJacobetal.[19]. Allinputparametersandcorrespondingreferences\narelistedinTable1.\nTable1.Inputparameters.\nPre-test-ProbabilityofBC 2.635 Jacobetal.[19]\nAgeatdiagnosticprocedure 60years USPreventiveServicesTaskForce[1]\nAssumedWTP USD100,000,00 Assumption\nDiscountrate 3.00% Assumption\nMarkovmodeltime 20years Assumption\nDiagnosticTestPerformances\nSensitivityforBCCT 77.9% Ardilaetal.[15]\nSpecificityforBCCT 87.7% Ardilaetal.[15]\nSensitivityforBCCT+AI 97.7% Ardilaetal.[15]\nSpecificityforBCCT+AI 98.4% Ardilaetal.[15]\nCosts(Acute)\nCT USD161.00 Medicare(71,250)[20]\nCosts(LongTerm)\nNoBC USD0.00\nFollowupiffalsepositive USD2256.00 tenHaafetal.[21]\nCurativetherapyBC/resectioncost USD36,305.00 Cowperetal.[22]\nBCundetected USD0 Assumption\nBCafterresection USD4283.00 tenHaafetal.[21]\nTherapyBC,palliative USD60,000.00 tenHaafetal.[21]\nDead USD0 AssumptionCancers2022,14,1729 4of11\nTable1.Cont.\nUtilities\nNoBC 1 Assumption\nFollowupiffalsepositive 0.98 Gareenetal.[23]\nCurativetherapyBC/resection 0.79 Gruttersetal.[24]\nBCundetected 1 Assumption\nBCafterresection 0.933 M\u00f6lleretal.[25]\nBCpalliative 0.63 Doyleetal.[26]\nDead 0 Assumption\nTransitionProbabilities\nVerificationofsuspiciousnoduleasnoBC 100% Assumption\nTheNationalLungScreeningTrial\nDeathifnoBCbutsuspiciousnodule 0.001(invasivediagnostics)+lifetables\nResearchTeam[2]\nTheNationalLungScreeningTrial\nResectionrateofBCafterearlydetection 75%\nResearchTeam[2]\nDeathaftercurativeresection 4.70% Greenetal./Tokeretal.[27,28]\nRecurrenceafterresection 9.80% Louetal.[29]\nDetectionofinitiallyundetectedBC 15%1st,40%2nd,100%3rdyear Scholtenetal.[30]\nDeathwithundetectedBC lifetables\nResectionrateofBCafterdelayed\n26% Hunbogietal.[31]\ndetection\nCancerStatFacts:LungandBronchus\nDeathwithpalliativecare 36%\nCancer,NationalCancerInstitute[32]\nDeathwithoutBC lifetables\nAI=artificialintelligence;BC=bronchialcancer;CT=computedtomography;QALY=qualityadjustedlifeyear;\nWTP=willingness-to-pay.\n2.3. DiagnosticTestPerformances\nSensitivityandspecificityvaluesforCTdetectionofBCwithandwithoutAIwere\nderivedfromtheliterature(Table1).\n2.4. Costs\nFrom a United States (US) healthcare perspective, costs were estimated based on\nMedicaredataandavailableliterature(Table1). Thelong-termcostsofthefollowupin\ncaseoffalsepositivewasestimatedatUSD2256includingthecostsforafollowupCT\nexaminationandapossiblebronchoscopyandbiopsy[21]. TheresectioncostsofBCwere\nsettoUSD36,305,accordingtoCowperetal.[22]. annualcostsofpalliativeBCpatients\nwereestimatedatUSD60,000[21].\n2.5. Utilities\nUtility is measured in the additional quality-adjusted life years (QALY) which are\ngainedthrougheachdiagnosticprocedure. Accordingtopreviousstudies,qualityoflife\n(QOL)forcurativeBCpatientswassetto0.79forthefirstyearafterresectionand0.933\nforthefollowingyears[24,25]. Inaccordancewiththeliterature,QOLforpalliativeBC\npatients wasset to0.63 [26]. These values werethen used forcalculations ina Markov\nmodelspecificallydesignedasmentionedabove.\n2.6. TransitionProbabilities\nTransitionprobabilitieswerederivedfromasystematicreviewoftherecentliterature\nandareshowninTable1. Probabilityofsuccessfulresectionof(early)detectedBCwas\nestimatedat75%, accordingtothenationallungscreeningtrialresearchteam[2]. Risk\nofsecondaryoccurrenceofcancer/metastasesafterresectionoftheprimarytumorwas\nassumedtobe9.80%[29]. Annualmortalityrateofcurativepatientswassetto4.7%andto\n36.0%forpalliativepatients[28,32,33].Cancers2022,14,1729 5of11\n2.7. Cost-EffectivenessAnalysis\nThecost-effectivenessanalysiswasperformedbasedonMarkovsimulationswitha\nruntimeof20years(20iterations)afterinitialdiagnosticprocedure. Thediscountratewas\nsetto3.0%andwillingness-to-paywassettoUSD100,000perQALYaccordingtocurrent\nrecommendations[18].\nInthebase-casescenario, cost-effectivenesswasdeterminedwithcostsofCT+AI\nidenticaltocostsofCTonly,meaningcostsofUSD0foradditionaluseofAI.Basedonthese\nresults,maximumcostsforAIwerecalculatedforseveralwillingness-to-paythresholds.\nFor evaluation of model uncertainty and influence of alteration of each variable on the\nmodel,adeterministicsensitivityanalysiswasperformed. Resultswerevisualizedina\ntornadodiagram.\nBasedontheMarkovmodel,Monte-Carlosimulationswereusedtoperformaproba-\nbilisticsensitivityanalysiswithatotalof30,000iterations. Thismethodisusedtoaccount\nforthevariationofinput-parametersamongdifferentindividuals.\n3. Results\n3.1. Cost-EffectivenessAnalysis\nSimulationsofatimehorizonof20yearsresultedinaveragecumulativecostsofUSD\n4310.82forCT+AIandUSD4378.44forCTifadditionaldiagnosticcostsfortheuseofAI\nweresettoUSD0inthebasecasescenario. Inthisscenario,averagecumulativeeffective-\nnesswasat13.76QALYsforCT+AIandat13.75QALYsforCT.Tobetterunderstandthe\nimpactofinputparametersonthemodel,costsandeffectivenessaswellasdistribution\nofthedifferentoutcomesareshowninFigure2. Differentoverallcostsandeffectiveness\nderivefromdifferentdistributionoftheoutcomes\u201ctruepositive\u201d,\u201cfalsenegative\u201d,\u201ctrue\nnegative\u201d, and \u201cfalse positive\u201d based on different sensitivity and specificity of the two\nCancers 2022, 13, x FOR PEER REVIEW 6 of 11\nmethods. Theincrementalcost-effectivenessratiointhebasecasescenariowasnegative,\nmeaningboth,lowercostandhighereffectivenessforCT+AI.\nFFiigguurree 22.. RRoollll--bbaacckko offt htheee ceocnoonmomicimc omdoedleslh oshwoinwgincgo sctsosatnsd aenfdfe cetfifveecntievsesnoefssth oefd tihffee rdeinftfeoruentcto omuets-.\ncomes. Distributions leading to overall costs and effectiveness are different for CT and CT + AI de-\nDistributionsleadingtooverallcostsandeffectivenessaredifferentforCTandCT+AIdependingon\npending on sensitivity and specificity of the two methods and indicated as probabilities. BC = bron-\nsensitivityandspecificityofthetwomethodsandindicatedasprobabilities.BC=bronchialcancer;\nchial cancer; CT = computed tomography; TP = true positive; TN = true negative; FP = false positive;\nCT=computedtomography;TP=truepositive;TN=truenegative;FP=falsepositive;FN=false\nFN = false negative; Prob = probability.\nnegative;Prob=probability.\nFigure 3. Probabilistic sensitivity analysis utilizing Monte-Carlo simulations (30,000 iterations). In-\ncremental cost-effectiveness scatter plot for CT + AI vs. CT. iterations with an ICER-value below theCancers 2022, 13, x FOR PEER REVIEW 6 of 11\nCancers2022,14,1729 6of11\n3.2. SensitivityAnalysis\nProbabilisticsensitivityanalysisandMonteCarlosimulationwasperformedtode-\nFtiegrumrei n2e. tRhoelld-biasctrki bouf ttihoen eocfonthoemrice smulotdinelg sIhCoEwRin-vga clousetss aanndd iesffvecistiuvaelniezsesd oifn thFeig duirfefe3re.nMt oountt-e\ncComarelso. sDimisturilbautitoionnrse lfleaedctinsgth teo dovifefrearlel nccoestbs eatnwde eefnfeccotisvtesn(e=sisn acrree mdifefnerteanltc ofosrt sC)Ta nadnde fCfeTc +ti vAeIn dees-s\npending on sensitivity and specificity of the two methods and indicated as probabilities. BC = bron-\n(=incremental effectiveness) for a certain amount of notional scenarios/iterations. All\nchial cancer; CT = computed tomography; TP = true positive; TN = true negative; FP = false positive;\niterationswithanICER-valuebelowthewillingness-to-payofUSD100,000perQALYwere\nFN = false negative; Prob = probability.\nconsideredcost-effective.\nFigure 3. Probabilistic sensitivity analysis utilizing Monte-Carlo simulations (30,000 iterations).\nFigure 3. Probabilistic sensitivity analysis utilizing Monte-Carlo simulations (30,000 iterations). In-\nIncrementalcost-effectivenessscatterplotforCT+AIvs.CT.iterationswithanICER-valuebelowthe\ncremental cost-effectiveness scatter plot for CT + AI vs. CT. iterations with an ICER-value below the\nwillingness-to-payofUSD100,000perQALYareshownasgreencrosses.WTP=willingness-to-pay.\nDeterministicsensitivityanalysiswasperformedtoaccountforvariabilityofinput\nparameters in the base case scenario. Results are displayed as a tornado diagram in\nFigure4A.\nApplyingwiderangesofvariationforthedifferentinputparameters,ICERstayed\nbelowUSD0/QALYforthesensitivitiesofthediagnosticmodalitiesandtheprobabilitiesof\nresectabilityinearlyanddelayeddiagnosis. AlthoughICERturnedpositivewhenvarying\nthespecificityofCTandCT+AI,thewillingness-to-paythresholdofUSD100,000/QALY\nwasnotcrossedinanyofthecases.\n3.3. ThresholdAnalysis\nTodeterminethemaximumpossiblecostsfortheuseofAIatawillingness-to-pay\nofUSD100,000/QALY,athresholdanalysiswasperformed. AsshowninFigure5,ICER\nremainednegativeuntilcostsofAIwereraisedtoUSD68.Cancers 2022, 13, x FOR PEER REVIEW 7 of 11\nwillingness-to-pay of USD 100,000 per QALY are shown as green crosses. WTP = willingness-to-\npay.\nDeterministic sensitivity analysis was performed to account for variability of input\nparameters in the base case scenario. Results are displayed as a tornado diagram in Figure\nCancers2022,14,1729 7of11\n4A.\nFigure 4. (A) Tornado diagram showing the impact of input parameters on incremental cost-\nFigure 4. (A) Tornado diagram showing the impact of input parameters on incremental cost-effec-\netfifveecntievsesn reastsiora (tIiCoE(IRC)E iRn) tihnet hbeasbea sceacsea ssecsecneanraiori.o A.Asssusmuminign ga awwilillilninggnneessss--ttoo--ppaayy tthhrreesshhoolldd ooff UUSSDD\n110000,,000000 ppeerr QQAALLYY,,C CTT+ +A AIIr reemmaainineeddc coosstt--eeffffeeccttiivvee iinna allllc caasseess.. ((BB)) TToorrnnaaddood diaiaggrraamm sshhoowwiinngg tthhee\niimmppaacctt ooff iinnppuutt ppaarraammeetteerrss oonn ininccrreemmeenntatal lcocosts-te-feffefcetcitvivenenesess srartaioti o(IC(IECRE)R w)hwehne cnocstoss otsf oAfI AwIewree sreet\nsteot UtoSDU S1D24102 w40itwh iatnh aexnpeexcpteedct vedaluvea loufe UoSfDU S1D001,00000,0 p0e0r pQeArQLYA.L BYl.uBel ubaerbs asrhsoswh ocwhacnhgaensg weshewnh deen-\ncreasing the value of an input parameter as compared to the base case scenario and red bars when\ndecreasingthevalueofaninputparameterascomparedtothebasecasescenarioandredbarswhen\nCancers 2022, 13, x FOR PEER REVIEinWc reasing the respective value. Sens = sensitivity; Spec = specificity; CT = computed tom8o ogfr 1a1p hy;\nincreasingtherespectivevalue.Sens=sensitivity;Spec=specificity;CT=computedtomography;\nAI = artificial intelligence; P = probability.\nAI=artificialintelligence;P=probability.\nApplying wide ranges of variation for the different input parameters, ICER stayed\nbelow USD 0/QALY for the sensitivities of the diagnostic modalities and the probabilities\nof resectability in early and delayed diagnosis. Although ICER turned positive when var-\nying the specificity of CT and CT + AI, the willingness-to-pay threshold of USD\n100,000/QALY was not crossed in any of the cases.\n3.3. Threshold Analysis\nTo determine the maximum possible costs for the use of AI at a willingness-to-pay of\nUSD 100,000/QALY, a threshold analysis was performed. As shown in Figure 5, ICER re-\nmained negative until costs of AI were raised to USD 68.\nFigure5.One-waysensitivityanalysisforcostsofAI(USD)andthecorrespondingincrementalcost\nFigure 5. One-way sensitivity analysis for costs of AI (USD) and the corresponding incremental cost\nefefeffcetcitviveenneessssr raattiioo ((IICCEERR iinn UUSSDD //QQAALLYY)).. TThhrreesshhooldlds sininddiciactaet evavlauleuse ast aatna nICIECRE oRf oUfSUDS 0D/Q0A/QLYA LY\nanadndU USDSD1 01000,0,00000//QQAALLYY.. IICCEERR == iinnccrreemmeenntatal lccoosts-te-feffefcetcivtievneenses srsartiaot;i oA;IA =I a=rtaifritciifialc iianlteinlltigeellnigcee;n ce;\nQQAALYLY= =q quuaaliltiytya addjujusstteedd lliiffee yyeeaarr..\nRaising costs of AI further, the assumed willingness-to-pay threshold of USD\n100,000/QALY is only crossed at a value USD 1240. Influence in different input parameters\nin this second base case scenario setting costs of AI to USD 1240 are shown in Figure 4B.\nTo account for possible variation of the willingness-to-pay, Table 2 displays possible costs\nfor AI depending on different willingness-to-pay thresholds. Due to the cost\u2019s depend-\nency on the ICER, the cost for AI directly is further influenced by the systems perfor-\nmance, resulting in a higher price for a better system due to the increased ICER.\nTable 2. Cost of AI at different WTP-thresholds.\n4. Discussion\nThe widespread integration of lung cancer screening is proving to be a complex and\nchallenging undertaking. Nevertheless, lung cancer screening is a cost-effective method\nto reduce lung cancer mortality. AI-models for cancer detection and classification have\nproved to be of benefit in lung cancer screening in several studies [15,34].\nIn the present study, we show that a state-of-the-art AI-model (3D-convolutional\nneural network according to Ardila et al.) is a cost-effective method for the baseline\nscreening scan [15]. Despite promising results of AI in the health care sector, studies eval-\nuating the economic impact and cost effectiveness remain sparse [35]. To our knowledge,Cancers2022,14,1729 8of11\nRaisingcostsofAIfurther,theassumedwillingness-to-paythresholdofUSD100,000/\nQALY is only crossed at a value USD 1240. Influence in different input parameters in\nthissecondbasecasescenariosettingcostsofAItoUSD1240areshowninFigure4B.To\naccountforpossiblevariationofthewillingness-to-pay,Table2displayspossiblecostsfor\nAIdependingondifferentwillingness-to-paythresholds. Duetothecost\u2019sdependency\non the ICER, the cost for AI directly is further influenced by the systems performance,\nresultinginahigherpriceforabettersystemduetotheincreasedICER.\nTable2.CostofAIatdifferentWTP-thresholds.\nWTP(USD/QALY) 0 20,000 40,000 60,000 80,000 100,000 120,000 150,000 200,000\nCostofAI(USD) 68 302 537 771 1006 1240 1475 1826 2412\n4. Discussion\nThewidespreadintegrationoflungcancerscreeningisprovingtobeacomplexand\nchallengingundertaking. Nevertheless,lungcancerscreeningisacost-effectivemethod\ntoreducelungcancermortality. AI-modelsforcancerdetectionandclassificationhave\nprovedtobeofbenefitinlungcancerscreeninginseveralstudies[15,34].\nInthepresentstudy,weshowthatastate-of-the-artAI-model(3D-convolutionalneural\nnetworkaccordingtoArdilaetal.) isacost-effectivemethodforthebaselinescreening\nscan[15]. DespitepromisingresultsofAIinthehealthcaresector,studiesevaluatingthe\neconomicimpactandcosteffectivenessremainsparse[35]. Toourknowledge,nostudy\nhasbeenconductedtoinvestigatethecost-effectivenessofanAI-systeminlungcancer\nscreening. BasedonthesuperiorperformanceoftheAI-modelwithoutpriorimaging,we\nsimulatedanimplementationfortheinitialscreeningscanusinginputparametersderived\nfrom published screening cohorts [2,15,36,37], to ensure comparability to the standard\nscreeningsetting.\nOur base case estimate for screening with an AI system compared to current low-\ndose CT screening yielded a negative ICER up to costs of USD 68 for the AI system,\nindicatingthatusinganAIsysteminthescreeningsettingresultsinlowercostandhigher\neffectivenessuptothesecostsperpatientscan. Furthermore,theICERremainedbelow\ntheappliedwillingness-to-payuptocostsofUSD1240. Toaccountforvariationsininput\nparameters,weperformedadeterministicsensitivityanalysisforthebasecasescenarioand\nthemaximumcost-effectivecosts(USD1240). Thespecificityofthediagnosticstrategyhad\nthegreatestinfluenceforbothscenarios,duetothelowlungcancerrateinscreeningcohorts.\nForthebasecasescenarioallinputvariationsresultedinanICERbelowthewillingness-to-\npaybyalargemargin,indicatingrobustcost-effectiveness. AddingAIsupportshowed\na reduced number of false-positives and an increased number of true negatives in our\nsimulation. In particular, the reduction of false-positives highly impacts the value of a\nscreeningmethod,asnotonlycostsintheformofunnecessaryfollow-upexaminationand\npossiblyfurther,partlyinvasiveexaminationsarereduced,butalsopatientsdonothave\ntoexperiencethepsychologicaldistressofapossiblecancerdiagnosis[38]. Additionally,\nthe false positive rates and the frequency of invasive diagnostic procedures were more\nfrequentatthebaselineCT,rangingfrom7.9%to49.3%forthefalsepositiverateand3.7%\nforadditionalinvasiveprocedures[2,39],furtheremphasizingthebenefitofAIsupportfor\ntheinitialscreening. AsshownbyAudelanetal.,thesensitivityandspecificityofAIin\nlungcancerscreeningcanfurtherbeimproved,consequentlyallowingforanadditional\nreductionofcostsandincreasedeffectiveness[40].\nDespite promising results, our study underlies several limitations. First, the cost-\neffectivenesswasonlyevaluatedfortheinitialscaninthelungcancerscreening. Thisis\nduetopublishedliterature,focusingonthesuperiorityofAIlungnoduledetectionand\nclassificationininitialCTofthethoraxwithoutpriorimagingforcomparison.Accordingto\nArdilaetal.,deep-learningalgorithmsaresuperiortoradiologistsinlungcancerscreening\ndetection, when no prior imaging is available for comparison, but is on-par as soon asCancers2022,14,1729 9of11\npreviousexaminationsareavailableforthereader. Consequently,furtherresearchhastobe\nconductedtoevaluatethecost-effectivenessofAI-basedcomputer-aideddiagnosissystems\ninlongitudinalscreening,beyondtheinitialscan[15]. Further,ourevaluationisfocused\nonthesoleAIsystemperformanceincomparisontothehumanreader\u2014theradiologist.\nHowever,severalstudieshaveshownpromisingresultsforthecollaborationofboth,often\nreferredtoasthe\u201cCentaurmodel\u201d[33]. Suchsystemswereshownnotonlytobebeneficial\nin patient care but cost-effective as well [41]. Despite dealing with different challenges\ncomparedtolungcancer, forthyroidnoduledetection, AIsystemsoutperformthyroid\ncancerspecializedradiologistsinnoduleclassification,butthecombinationofspecialized\nradiologistswithAI-supportshowedanevenhigherspecificityandpositivepredictive\nvaluewhencomparedtotheAIsystemalone[42]. Therefore,furtherresearchisneeded\nto evaluate the combination of AI models and specialized thorax radiologists in lung\ncancerdetectionanditscost-effectiveness. Lastly,cost-effectivenessanalysiswithdecision-\nbasedmodelsishighlydependentontheinputparameters,whiledeterministicsensitivity\nanalysismayincorporateparametervariationtoacertaindegree,andrecommendations\nforeachindividualcasecannotbederivedfromthemodel.\n5. Conclusions\nTo conclude, in our study we show that screening with an AI-model in the initial\nscreening scan is a cost-effective strategy in low-dose CT lung cancer screening with\nrobustnesstovariationofinputparameters. DefiningthresholdsforcostofAIresultsmight\nhelpfastertranslateAIsystemsintoclinicaluse.\nAuthorContributions: Conceptualization, S.Z.andF.G.; methodology, F.G.andJ.G.; validation,\nM.G.,S.Z.;formalanalysis,F.G.;investigation,S.Z.,M.G.andJ.G.;resources,M.M.;datacuration\nM.G.;writing\u2014originaldraftpreparation,S.Z.andJ.G.;writing\u2014reviewandediting,M.G.,F.G.and\nM.M.;visualization,F.G.Allauthorshavereadandagreedtothepublishedversionofthemanuscript.\nFunding:Thisresearchreceivednoexternalfunding.\nInstitutionalReviewBoardStatement:Ethicalreviewandapprovalwerewaivedforthisstudydue\ntothisanalysisisbasedoncommonlyavailabledata.\nInformedConsentStatement:Notapplicable.\nDataAvailabilityStatement:ThedatathatsupportthefindingsofthisstudyarelistedinTable1.\nConflictsofInterest:Theauthorsdeclarenoconflictofinterest.\nReferences\n1. MoyerVirginia,A.Onbehalfoftheuspreventiveservicestaskforcescreeningforlungcancer:Uspreventiveservicestaskforce\nrecommendationstatement.Ann.Intern.Med.2014,160,330\u2013338.\n2. NationalLungScreeningTrialResearchTeam.Reducedlung-cancermortalitywithlow-dosecomputedtomographicscreening.\nN.Engl.J.Med.2011,365,395\u2013409.[CrossRef][PubMed]\n3. Oudkerk,M.;Devaraj,A.;Vliegenthart,R.;Henzler,T.;Prosch,H.;Heussel,C.P.;Bastarrika,G.;Sverzellati,N.;Mascalchi,M.;\nDelorme,S.Europeanpositionstatementonlungcancerscreening.LancetOncol.2017,18,e754\u2013e766.[PubMed]\n4. DeKoning,H.J.;vanderAalst,C.M.;deJong,P.A.;Scholten,E.T.;Nackaerts,K.;Heuvelmans,M.A.;Lammers,J.-W.J.;Weenink,\nC.;Yousaf-Khan,U.;Horeweg,N.Reducedlung-cancermortalitywithvolumectscreeninginarandomizedtrial.N.Engl.J.Med.\n2020,382,503\u2013513.[CrossRef][PubMed]\n5. Rasmussen,J.F.; Siersma,V.; Pedersen,J.H.; Heleno,B.; Saghir,Z.; Brodersen,J.Healthcarecostsinthedanishrandomised\ncontrolledlungcancerct-screeningtrial:Aregistrystudy.LungCancer2014,83,347\u2013355.[CrossRef]\n6. Wiener,R.S.;Schwartz,L.M.;Woloshin,S.;Welch,H.G.Population-basedriskforcomplicationsaftertransthoracicneedlelung\nbiopsyofapulmonarynodule:Ananalysisofdischargerecords.Ann.Intern.Med.2011,155,137\u2013144.[CrossRef]\n7. Kastner,J.;Hossain,R.;Jeudy,J.;Dako,F.;Mehta,V.;Dalal,S.;Dharaiya,E.;White,C.Lung-radsversion1.0versuslung-rads\nversion1.1:Comparisonofcategoriesusingnodulesfromthenationallungscreeningtrial.Radiology2021,300,203704.\n8. McKee,B.J.;Regis,S.M.;McKee,A.B.;Flacke,S.;Wald,C.Performanceofacrlung-radsinaclinicalctlungscreeningprogram.J.\nAm.Coll.Radiol.2016,13,R25\u2013R29.[CrossRef]\n9. Mehta,H.J.;Mohammed,T.-L.;Jantz,M.A.Theamericancollegeofradiologylungimagingreportinganddatasystem:Potential\ndrawbacksandneedforrevision.Chest2017,151,539\u2013543.[CrossRef]Cancers2022,14,1729 10of11\n10. Singh,S.;Pinsky,P.;Fineberg,N.S.;Gierada,D.S.;Garg,K.;Sun,Y.;Nath,P.H.Evaluationofreadervariabilityintheinterpretation\noffollow-upctscansatlungcancerscreening.Radiology2011,259,263\u2013270.[CrossRef]\n11. McKinney,S.M.;Sieniek,M.;Godbole,V.;Godwin,J.;Antropova,N.;Ashrafian,H.;Back,T.;Chesus,M.;Corrado,G.S.;Darzi,A.\nInternationalevaluationofanaisystemforbreastcancerscreening.Nature2020,577,89\u201394.[CrossRef][PubMed]\n12. Brown,M.S.;Goldin,J.G.;Rogers,S.;Kim,H.J.;Suh,R.D.;McNitt-Gray,M.F.;Shah,S.K.;Truong,D.;Brown,K.;Sayre,J.W.\nComputer-aidedlungnoduledetectioninct:Resultsoflarge-scaleobservertest1. Acad. Radiol. 2005,12,681\u2013686. [CrossRef]\n[PubMed]\n13. DeHoop,B.;deBoo,D.W.;Gietema,H.A.;vanHoorn,F.;Mearadji,B.;Schijf,L.;vanGinneken,B.;Prokop,M.;Schaefer-Prokop,\nC.Computer-aideddetectionoflungcanceronchestradiographs:Effectonobserverperformance.Radiology2010,257,532\u2013540.\n[CrossRef][PubMed]\n14. Jeon,K.N.;Goo,J.M.;Lee,C.H.;Lee,Y.;Choo,J.Y.;Lee,N.K.;Shim,M.-S.;Lee,I.S.;Kim,K.G.;Gierada,D.S.Computer-aided\nnoduledetectionandvolumetrytoreducevariabilitybetweenradiologistsintheinterpretationoflungnodulesatlow-dose\nscreeningct.Investig.Radiol.2012,47,457.[CrossRef]\n15. Ardila,D.;Kiraly,A.P.;Bharadwaj,S.;Choi,B.;Reicher,J.J.;Peng,L.;Tse,D.;Etemadi,M.;Ye,W.;Corrado,G.End-to-endlung\ncancerscreeningwiththree-dimensionaldeeplearningonlow-dosechestcomputedtomography.Nat.Med.2019,25,954\u2013961.\n[CrossRef]\n16. Arias,E.;Xu,J.;Kochanek,K.D.Unitedstateslifetables,2016.Natl.VitalStat.Rep.2019,68,4.\n17. Cameron,D.;Ubels,J.Norstr\u00f6mf:Onwhatbasisaremedicalcost-effectivenessthresholdsset.ClashingOpin.AbsenceDataA\nSyst.Rev.Glob.HealthAction2018,11,1447828.[CrossRef]\n18. Sanders,G.D.;Neumann,P.J.;Basu,A.;Brock,D.W.;Feeny,D.;Krahn,M.;Kuntz,K.M.;Meltzer,D.O.;Owens,D.K.;Prosser,\nL.A.Recommendationsforconduct,methodologicalpractices,andreportingofcost-effectivenessanalyses: Secondpanelon\ncost-effectivenessinhealthandmedicine.JAMA2016,316,1093\u20131103.[CrossRef]\n19. Jacob,L.;Freyn,M.;Kalder,M.;Dinas,K.;Kostev,K.Impactoftobaccosmokingontheriskofdeveloping25differentcancersin\ntheuk:Aretrospectivestudyof422,010patientsfollowedforupto30years.Oncotarget2018,9,17420.[CrossRef]\n20. ProcedurePriceLookupforOutpatientServices. Medicare.gov71275. 2021. Availableonline: https://www.medicare.gov/\nprocedure-price-lookup/cost/71275/(accessedon9January2022).\n21. TenHaaf,K.;Tammem\u00e4gi,M.C.;Bondy,S.J.;vanderAalst,C.M.;Gu,S.;McGregor,S.E.;Nicholas,G.;deKoning,H.J.;Paszat,L.F.\nPerformanceandcost-effectivenessofcomputedtomographylungcancerscreeningscenariosinapopulation-basedsetting:A\nmicrosimulationmodelinganalysisinOntario,Canada.PLoSMed.2017,14,e1002225.[CrossRef]\n22. Cowper,P.A.; Feng,L.; Kosinski,A.S.; Tong,B.C.; Habib,R.H.; Putnam,J.B.,Jr.; Onaitis,M.W.; Furnary,A.P.; Wright,C.D.;\nJacobs,J.P.Initialandlongitudinalcostofsurgicalresectionforlungcancer.Ann.Thorac.Surg.2021,111,1827\u20131833.[CrossRef]\n[PubMed]\n23. Gareen, I.F.; Duan, F.; Greco, E.M.; Snyder, B.S.; Boiselle, P.M.; Park, E.R.; Fryback, D.; Gatsonis, C. Impact of lung cancer\nscreeningresultsonparticipanthealth-relatedqualityoflifeandstateanxietyinthenationallungscreeningtrial.Cancer2014,\n120,3401\u20133409.[CrossRef][PubMed]\n24. Grutters,J.P.;Joore,M.A.;Wiegman,E.M.;Langendijk,J.A.;deRuysscher,D.;Hochstenbag,M.;Botterweck,A.;Lambin,P.;\nPijls-Johannesma,M.Health-relatedqualityoflifeinpatientssurvivingnon-smallcelllungcancer. Thorax2010,65,903\u2013907.\n[CrossRef]\n25. M\u00f6ller,A.;Sartipy,U.Long-termhealth-relatedqualityoflifefollowingsurgeryforlungcancer.Eur.J.Cardio-Thorac.Surg.2012,\n41,362\u2013367.[CrossRef][PubMed]\n26. Doyle,S.;Lloyd,A.;Walker,M.Healthstateutilityscoresinadvancednon-smallcelllungcancer.LungCancer2008,62,374\u2013380.\n[CrossRef][PubMed]\n27. Green,A.;Hauge,J.;Iachina,M.;Jakobsen,E.Themortalityaftersurgeryinprimarylungcancer:Resultsfromthedanishlung\ncancerregistry.Eur.J.Cardio-Thorac.Surg.2016,49,589\u2013594.[CrossRef]\n28. Toker,A.;Dilege,S.;Ziyade,S.;Eroglu,O.;Tanju,S.;Yilmazbayhan,D.;Kilicarslan,Z.;Kalayci,G.Causesofdeathwithin1year\nofresectionforlungcancer.Earlymortalityafterresection.Eur.J.Cardio-Thorac.Surg.2004,25,515\u2013519.[CrossRef]\n29. Lou,F.;Huang,J.;Sima,C.S.;Dycoco,J.;Rusch,V.;Bach,P.B.Patternsofrecurrenceandsecondprimarylungcancerinearly-stage\nlungcancersurvivorsfollowedwithroutinecomputedtomographysurveillance.J.Thorac.Cardiovasc.Surg.2013,145,75\u201382.\n[CrossRef][PubMed]\n30. Scholten,E.T.;Horeweg,N.;deKoning,H.J.;Vliegenthart,R.;Oudkerk,M.;Willem,P.T.M.;deJong,P.A.Computedtomographic\ncharacteristicsofintervalandpostscreencarcinomasinlungcancerscreening.Eur.Radiol.2015,25,81\u201388.[CrossRef]\n31. Thorsteinsson,H.;Alexandersson,A.;Oskarsdottir,G.N.;Skuladottir,R.;Isaksson,H.J.;Jonsson,S.;Gudbjartsson,T.Resection\nrateandoutcomeofpulmonaryresectionsfornon\u2013small-celllungcancer:Anationwidestudyfromiceland.J.Thorac.Oncol.\n2012,7,1164\u20131169.[CrossRef]\n32. CancerStatFacts: LungandBronchusCancer. 2021. Availableonline: https://seer.cancer.gov/statfacts/html/lungb.html\n(accessedon9January2022).\n33. Goldstein,I.M.;Lawrence,J.;Miner,A.S.Human-machinecollaborationincancerandbeyond:Thecentaurcaremodel.JAMA\nOncol.2017,3,1303\u20131304.[CrossRef][PubMed]Cancers2022,14,1729 11of11\n34. Liang,M.;Tang,W.;Xu,D.M.;Jirapatnakul,A.C.;Reeves,A.P.;Henschke,C.I.;Yankelevitz,D.Low-dosectscreeningforlung\ncancer:Computer-aideddetectionofmissedlungcancers.Radiology2016,281,279\u2013288.[CrossRef][PubMed]\n35. Wolff,J.;Pauling,J.;Keck,A.;Baumbach,J.Systematicreviewofeconomicimpactstudiesofartificialintelligenceinhealthcare.J.\nMed.InternetRes.2020,22,e16866.[CrossRef][PubMed]\n36. Pastorino,U.;Rossi,M.;Rosato,V.;Marchian\u00f2,A.;Sverzellati,N.;Morosi,C.;Fabbri,A.;Galeone,C.;Negri,E.;Sozzi,G.Annual\norbiennialctscreeningversusobservationinheavysmokers:5-yearresultsofthemildtrial.Eur.J.CancerPrev.2012,21,308\u2013315.\n[CrossRef]\n37. VanKlaveren,R.J.;Oudkerk,M.;Prokop,M.;Scholten,E.T.;Nackaerts,K.;Vernhout,R.;vanIersel,C.A.;vandenBergh,K.A.;\nWesteinde,S.V.;vanderAalst,C.Managementoflungnodulesdetectedbyvolumectscanning. N.Engl. J.Med. 2009,361,\n2221\u20132229.[CrossRef]\n38. VandenBergh,K.A.;Essink-Bot,M.-L.;Borsboom,G.J.;Scholten,E.T.;Prokop,M.;deKoning,H.J.;vanKlaveren,R.J.Short-term\nhealth-relatedqualityoflifeconsequencesinalungcancerctscreeningtrial(nelson).Br.J.Cancer2010,102,27\u201334.[CrossRef]\n39. Jonas,D.E.;Reuland,D.S.;Reddy,S.M.;Nagle,M.;Clark,S.D.;Weber,R.P.;Enyioha,C.;Malo,T.L.;Brenner,A.T.;Armstrong,\nC.Screeningforlungcancerwithlow-dosecomputedtomography:Updatedevidencereportandsystematicreviewfortheus\npreventiveservicestaskforce.JAMA2021,325,971\u2013987.[CrossRef]\n40. Audelan, B.; Lopez, S.; Fillard, P.; Diascorn, Y.; Padovani, B.; Delingette, H.ValidationofLungNoduleDetectionaYearbefore\nDiagnosisinNlstDatasetBasedonaDeepLearningSystem;EuropeanRespiratorySociety:Lausanne,Switzerland,2021.\n41. Hoverman,J.R.;Klein,I.;Harrison,D.W.;Hayes,J.E.;Garey,J.S.;Harrell,R.;Sipala,M.;Houldin,S.;Jameson,M.D.;Abdullahpour,\nM.Openingtheblackbox:Theimpactofanoncologymanagementprogramconsistingoflevelipathwaysandanoutbound\nnursecallsystem.J.Oncol.Pract.2014,10,63\u201367.[CrossRef]\n42. Peng,S.;Liu,Y.;Lv,W.;Liu,L.;Zhou,Q.;Yang,H.;Ren,J.;Liu,G.;Wang,X.;Zhang,X.Deeplearning-basedartificialintelligence\nmodeltoassistthyroidnodulediagnosisandmanagement:Amulticentrediagnosticstudy.LancetDigit.Health2021,3,e250\u2013e259.\n[CrossRef]"
}